A Randomized Phase 2 Trial of Neoadjuvant Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Patients With Localized Renal Cell Carcinoma.

NCT07593040 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant/Adjuvant Renal Cell Carcinoma

Interventions

DRUG: Neoadjuvant Pembrolizumab
DRUG: Belzutifan
DRUG: Lenvatinb

Sponsor

Vall d'Hebron Institute of Oncology